The demand for donated blood is rising because of advancements in healthcare systems and the availability of and the need for sophisticated surgical procedures, such as cardiovascular & transplant surgery, trauma care, and therapy for cancer and blood diseases. Emerging economies such as China, Japan, and India are providing lucrative opportunities for the players operating in the market.
The global Blood screening market is projected to reach USD 3.8 billion by 2026 from USD 2.5 billion in 2021, at a CAGR of 8.4%.
Download PDF Brochure:- https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=267747042
Scope of the Report
This report categorizes the blood screening market into the following segments and subsegments:
By Product & Service
Reagents & Kits
NAT Reagents & Kits
Enzymes & Polymerases
Standards & Controls
Probes & Primers
Buffers, Nucleotides, and Solutions
Labeling & Detection Reagents
ELISA Reagents & Kits
Immunosorbents
Controls
Conjugates
Substrates
Sample Diluents & Wash Solutions
Other Reagents & Kits
Instruments
Rental Purchase
Outright Purchase
Software & Services
By Technology
Nucleic Acid Test
Transcription-mediated Amplification
Real-time PCR
ELISA
Chemiluminescent Immunoassays
Fluorescent Immunoassays
Colorimetric Immunoassays
Rapid Tests
Western Blot Assays
Next-generation Sequencing
By End User
Blood Banks
Hospitals
By Region
North America
US
Canada
Europe
Germany
UK
France
Italy
Spain
Rest of Europe
Asia Pacific
China
Japan
India
Australia
Rest of Asia Pacific
Latin America
Australia
Rest of Latin America
Middle East & Africa
Market Segmentation: -
The blood screening market is segmented into reagents & kits, instruments, and software & services. The reagents & kits accounted for the largest share of the market in 2020, mainly due to repeated use of reagents & kits in blood screening procedures due to the rising blood transfusion procedures, and the high consumption.
The blood screening market is segmented into nucleic acid test (NAT), enzyme-linked immunosorbent assay (ELISA), rapid tests, western blot assays, and next-generation sequencing (NGS). In 2020, the nucleic acid test (NAT) segment accounted for the largest share of the market. Factors such as the increasing adoption of NAT technology due to its higher sensitivity over other blood screening technologies and increasing number of blood donations.
Based on end users, the blood screening market is segmented into blood banks and hospitals. In 2020, the blood banks segment accounted for the largest share of the market. The growing number of organ transplantation surgeries is driving the growth of this segment, and the increasing demand for donated blood.
Regional Analysis:
The global market is segmented into five major regions—north America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. In 2020, North America accounted for the largest share of the market. The North American market growth can be attributed to the increasing healthcare spending, increasing prevalence of chronic disorders, and the highly developed healthcare system in the US and Canada.
Request Sample Pages:- https://www.marketsandmarkets.com/requestsampleNew.asp?id=267747042
Top key Players:-
The major players operating in this blood screening market are Grifols (Spain), F. Hoffmann-La Roche Ltd. (Switzerland), Abbott Laboratories, Inc. (US), bioMérieux (France), Bio-Rad Laboratories, Inc. (US), Becton, Dickinson and Company (US), Beckman Coulter, Inc. (Danaher) (US), DiaSorin (Italy), Siemens Healthineers (Germany), Thermo Fisher Scientific, Inc. (US), Ortho Clinical Diagnostics Inc. (US), GE Healthcare (US), Merck KGaA (Germany), PerkinElmer (US), Bio-Techne Corporation (US), GFE (Germany), Trinity Biotech (Ireland), Mindray (China), Maccura Biotechnology Co., Ltd. (China), Immucor, Inc. (US), Cellabs (Australia), Abnova Corporation (Taiwan), Enzo Biochem, Inc. (US), and Cepheid (US).
コメント